# Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma

> **NCT01588704** · PHASE2 · COMPLETED · sponsor: **Si-Yu Wang** · enrollment: 42 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Neoadjuvant Bevacizumab

## Key facts

- **NCT ID:** NCT01588704
- **Lead sponsor:** Si-Yu Wang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2014-01
- **Final completion:** 2014-04
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2015-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01588704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01588704, "Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01588704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*